- Incyte Corporation INCY reported Q1 earnings of $0.67, better than the consensus of $0.64, but sales of $604.7 million fell short of expectations of $659.2 million.
- Overall product and royalty revenues increased 6% Y/Y stemming from a 1% increase in Jakafi's (ruxolitinib) net product revenues of $465.7 million, the launch of Pemazyre, and higher product royalty revenues from Jakavi and Olumiant.
- A decline in new patient starts impacted the growth rate of Jakafi due to the COVID-19 pandemic and typical seasonal effects.
- Cash and equivalents totaled $2.0 billion.
- Guidance: Incyte reaffirmed FY21 Jakafi Net Product Revenues $2.125 - $2.2 billion.
- Price Action: INCY shares are down 4.47% at $81.7 during the market trading session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
